GPX4 and diffuse large B-cell lymphoma: In addition to these in vitro studies as mentioned above, recent clinical research (131) has precisely shown that the expression rate of GPX4 was 35.5% (33/93) in DLBCL patients, and the overall survival and progression-free survival of the GPX4-positive group were worse than those of the GPX4-negative group.